A Review of Intraperitoneal Therapy of Human Ovarian Carcinoma
Open Access
- 1 April 1983
- journal article
- review article
- Published by SAGE Publications in Peritoneal Dialysis International
- Vol. 3 (2), 59-62
- https://doi.org/10.1177/089686088300300204
Abstract
Ovarian carcinoma disseminates by direct seeding throughout the peritoneal cavity. It involves surfaces of the abdominal viscera, as well as the diaphragm. Epithelial ovarian carcinoma responds to multiple-agent chemotherapy, if tumor implants are reduced to 1.5 cm in any single location by cytoreductive surgery. Greater antitumor activity than that achieved by systemic administration may be obtained by increasing the dose and getting high concentrations of the chemotherapeutic agent directly to the site of the residual tumor. Oncologists have administered adriamycin into the peritoneal space using a permanent peritoneal dialysis catheter. Adriamycin added into two liters of dialysis solution can reach concentrations up to 400 times greater than those in plasma. The factor which limits the dose of intraperitoneal adriamycin is chemical peritonitis. Recently investigators have infused cis-diammine dichloro-platinum (CDDP) via the dialysis catheter. With this agent, four patients of 18 who had failed previous chemotherapy, showed an objective response. Finally, Corynebacterium parvum has also been administered intraperitoneally via the dialysis catheter. The permanent peritoneal catheter has at least two advantages: First, it permits intraperitoneal administration of the various chemotherapeutic agents, and second it permits easy sampling of the dialysis fluid for cytological analysis and for measurement of the peritoneal inflammatory activity, using antibody-dependent cell-mediated cytotoxicity assay. A new study now in progress will test the effect of recombinant interferon administered intraperitoneally to patients with ovarian cancer.Keywords
This publication has 8 references indexed in Scilit:
- Intraperitoneal Cisplatin with Systemic Thiosulfate ProtectionAnnals of Internal Medicine, 1982
- Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer PatientsAnnals of Internal Medicine, 1982
- Reactivity of a monoclonal antibody with human ovarian carcinoma.JCI Insight, 1981
- SENSITIVITY OF HUMAN OVARIAN CARCINOMA CELLS TO INTERFERON AND OTHER ANTITUMOR AGENTS AS ASSESSED BY AN IN VITRO SEMI‐SOLID AGAR TECHNIQUE*Annals of the New York Academy of Sciences, 1980
- Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer modelAmerican Journal of Obstetrics and Gynecology, 1977
- Management of Ovarian CarcinomaNew England Journal of Medicine, 1976
- Aortic lymph node metastases in early ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1974